论文部分内容阅读
目的 为探讨国产降纤酶治疗急性脑梗死的确切疗效和安全性。 方法 我科参加了由全国脑防办牵头并有全国 4 0多家大医院神经科参加的多中心随机、双盲对照临床验证工作。 结果 降纤酶对急性脑梗死总有效率达 61 % ,用降纤酶第 2天血纤维蛋白原开始下降 ,第 4天下降明显 ,以后基本无变化 ,而对照组在治疗后血纤维蛋白原基本无变化 ;从用降纤酶后总的趋势来看 ,PT有延长 ;对神经功能恢复及日常生活能力改善不明显。从安全性来看 ,未出现颅内出血等不良反应 ,对肝肾功能无影响。 结论 降纤酶能降低血纤维蛋白原 ,有溶栓的药理作用 ,且使 PT延长 ,对急性脑梗死有一定的防治作用
Objective To investigate the definitive efficacy and safety of domestic defibrase in the treatment of acute cerebral infarction. Methods Our department participated in a multi-center, randomized, double-blind, controlled clinical trial led by the National Brain Defense Agency and attended by more than 40 major hospitals in the country. Results: The total effective rate of defibrase on acute cerebral infarction was 61%. The level of fibrinogen in defibrase began to decrease on the second day, decreased significantly on the fourth day and remained unchanged afterwards. In the control group, fibrinogen Basically no change; from defibrase after the general trend of view, PT has been extended; on neurological function and daily life improvement is not obvious. From the safety point of view, no adverse reactions such as intracranial hemorrhage, no effect on liver and kidney function. Conclusion defibrase can reduce the fibrinogen, thrombolytic pharmacological effects, and to prolong PT on acute cerebral infarction have a preventive effect